4-[2-(4-fluorophenyl)-4-piperidin-4-yl-1H-pyrrol-3-yl]pyridine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 英文名称: 4-[2-(4-fluorophenyl)-4-piperidin-4-yl-1H-pyrrol-3-yl]pyridine
• 英文别名: 2-(4-fluorophenyl)-4-(piperidin-4-yl)-3-(pyridin-4-yl)-1H-pyrrole
• 化学式: C₂₀H₂₀FN₃
• 分子量: 321.397
• InChiKey: JHQCFWJYMBINJL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-(4-fluorophenyl)-3-(pyridin-4-yl)-4-(1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrole dihydrochloride 在 钯 氢气 、 水 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以to give 84 mg (yield 85%) of the title compound as a pale red powder的产率得到4-[2-(4-fluorophenyl)-4-piperidin-4-yl-1H-pyrrol-3-yl]pyridine
  参考文献：
  名称：

  Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses

  摘要：

  具有针对式(I)'炎性细胞因子生成活性的化合物：A'为吡咯基；R1'为苯基或萘基；R2'为吡啶基或嘧啶基；R3'为(IIa)'、(IIb)'或(IIc)'；m'为1；E'为氮；D'为>C(R5')—，R5'为氢、取代基α'或取代基β'；B'为含氮5元杂环；R4'为取代基α'、取代基β'和取代基γ'中的1至3个取代基；R1'和R3'与相邻于与R2'键合的吡咯原子的两个原子键合；取代基α'为羟基、硝基、氰基、卤素、烷氧基、卤素烷氧基、烷硫基、卤素烷硫基或—NRa'Rb'；Ra'和Rb'为氢、烷基、烯基、炔基、芳基烷基或烷基磺酰基，或Ra'和Rb'与氮原子形成杂环；取代基β'为烷基、烯基、炔基、芳基烷基或环烷基；取代基γ'为氧代、羟肟代、烷氧肟代、烷基、烷基二氧、烷基亚磺酰基、烷基磺酰基、芳基、芳氧基、烷基亚甲基或芳基亚甲基。

  公开号：

  US07122666B2

文献信息

• Heteroaryl-substituted pyrrole derivates, their preparation and their therapeutic uses
  申请人：Sankyo Company Limited

  公开号：EP1243589A1

  公开（公告）日：2002-09-25

  Compounds of formula (I): [wherein: A is a pyrrole ring; R1 is an optionally substituted phenyl or naphthyl group; R2 is an optionally substituted pyridyl or pyrimidinyl group; R3 represents a group of the formula -X-R4, wherein X is a single bond or an alkenylene group, and R4 is an optionally substituted nitrogen-containing heterocyclyl group; selected from the group consisting of 8-azabicyclo[3.2.1]octenyl, 9-azabicyclo[3.3.1]nonenyl and quinuclidinenyl groups, PROVIDED THAT said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded] have excellent inhibitory activity against the production of inflammatory cytokines.

  化合物的结构式（I）：[其中：A为吡咯环；R1为可选取代的苯或萘基团；R2为可选取代的吡啶或嘧啶基团；R3代表具有下述结构的基团-X-R4，其中X为单键或烯基链，R4为可选取代的含氮杂环基团；所选取自8-氮杂双环[3.2.1]辛烯基、9-氮杂双环[3.3.1]壬烯基和喹啉环基团，前提是所述取代基R1和R3连接到所述吡咯环的两个相邻原子，这两个原子与所述取代基R2连接的吡咯环原子相邻]具有出色的抑制炎症细胞因子产生活性。
• COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY
  申请人：Sankyo Company, Limited

  公开号：EP1352906A1

  公开（公告）日：2003-10-15

  [Object] The object of the present invention is to provide a composition for the prophylaxis or treatment of hepatopathy. [Solution] A composition containing as an active ingredient a compound of formula (I), or a pharmacologically acceptable salt, ester or other derivative thereof for the prophylaxis or treatment of hepatopathy: [wherein: A is a pyrrole ring; R1 is an optionally substituted aryl or heteroaryl group; R2 is an optionally substituted heteroaryl group; R3 represents a group of the formula -X-R4, wherein X is a single bond or an optionally substituted alkylene, alkenylene or alkynylene group, and R4 is a substituted cycloalkyl group, a substituted aryl group, an optionally substituted heterocyclyl group, an optionally substituted heteroaryl group, or -NRaRb, wherein each of Ra and Rb is a hydrogen atom or an alkyl, alkenyl, alkynyl, aralkyl or alkylsulfonyl group; PROVIDED THAT said substituents R1 and R3 are bonded to the two atoms of said pyrrole ring which are adjacent to the atom of the pyrrole ring to which said substituent R2 is bonded].

  目的 本发明的目的是提供一种用于预防或治疗肝病的组合物。 [解决方案］ 一种含有式(I)化合物或其药理学上可接受的盐、酯或其他衍生物作为活性成分的组合物，用于预防或治疗肝病： 其中A 是吡咯环； R1 是任选取代的芳基或杂芳基； R2 是任选取代的杂芳基；R3代表式-X-R4的基团，其中X是单键或任选取代的亚烷基、亚烯基或亚炔基，R4是取代的环烷基、取代的芳基、任选取代的杂环烷基、任选取代的杂芳基，或-NRaRb，其中Ra和Rb各自是氢原子或烷基、烯基、炔基、芳基或烷基磺酰基；前提是所述取代基 R1 和 R3 与所述吡咯环的两个原子键合，这两个原子与所述取代基 R2 键合的吡咯环原子相邻]。
• EP1352906
  申请人：——

  公开号：——

  公开（公告）日：——
• Tetrahydropyridine derivatives with inhibitory activity on the production of proinflammatory cytokines: Part 1
  作者：Akira Nakao、Nobuyuki Ohkawa、Takayoshi Nagasaki、Takashi Kagari、Hiromi Doi、Takaichi Shimozato、Shigeru Ushiyama、Kazumasa Aoki

  DOI：10.1016/j.bmcl.2009.06.094

  日期：2009.8

  We investigated proinflammatory cytokine TNF alpha production inhibitors in order to develop novel anti-inflammatory agents. According to the results, we found that 17, a pyrrole derivative possessing a tetrahydropyridine group at the beta-position, showed potent inhibitory activity in vitro (inhibition of lipopolysaccharide (LPS) induced TNF alpha production in human whole blood, IC(50) = 1.86 mu M) and in vivo (inhibition of LPS induced TNF alpha production in mice, ID(50) = 5.98 mg/kg). Crown Copyright (C) 2009 Published by Elsevier Ltd. All rights reserved.
• US7122666B2
  申请人：——

  公开号：US7122666B2

  公开（公告）日：2006-10-17